Purchase Order 75F40124P00378
Award Date
8/29/24
Potential Completion Date
9/21/28
Potential Value
$175K
Federal Agency
Food and Drug Administration
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
NAICS Category
541519 - Other Computer Related Services
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Human Genome Research Institute awarded a $15,000 purchase order to Illumina, Inc. to provide DRAGEN CS LVL 1 LICENSE THROUGHPUT OF 100,000GB under contract number E21C6L5011010032. The one-year contract, which runs from July 2025 through July 2026, calls for Illumina to deliver genomic sequencing software licensing and throughput on a firm fixed price basis, to be billed quarterly in arrears. As the prime...
This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the delivery of a "HIGH-THROUGHPUT DESKTOP SEQUENCER WITH DATA ANALYSIS SYSTEM" and has a ceiling value of $426,000.30. There is no set-aside designation for this contract. Illumina has previously provided a range of sequencing systems, reagents, and...
This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract has a ceiling value of $924,805.20 and a period of performance ending on March 23, 2019. The award is for the provision of high-throughput sequencing equipment and services, with no set-aside designation. Illumina has a history of supporting genomic sequencing and analysis requirements across various...
This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a diagnostic check and system upgrades for the MiSeq Whole Genome Sequencer at six FDA laboratories. The $84,733.20 contract has a completion date of December 31, 2022 and was sole-sourced to Illumina due to the proprietary nature of the MiSeq technology. Illumina has previously provided sequencing systems,...
This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc. for $170,153.16 to provide annual on-site preventative maintenance service and unlimited repairs as needed on two Illumina MiSeq whole genome sequencers for a base year plus four option years. The contract has no set-aside designation. Based on Illumina's history as a prime contractor and subcontractor for sequencing systems and services across various federal agencies, this award aligns...
This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the service and maintenance of one Illumina MiSeq sequencing system, with a ceiling value of $34,972.40 and a performance period ending on September 24, 2024. Illumina, a for-profit organization and manufacturer of goods, has been awarded numerous prime federal contracts and...
This firm fixed-price purchase order in the amount of $115,987.29 was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the provision of a MiniSeq System, reagents, and post-warranty services, with a performance period ending on September 30, 2016. While the original solicitation is not provided, the products and services being delivered under this contract can be...
This firm fixed price purchase order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies, to provide one Illumina NextSeq 2000 Sequencer along with post-warranty correction and remedial repair services. The contract has a ceiling value of $534,536 and a performance period through December 11, 2028. There is no set-aside designation for this procurement. The contract was awarded in response to a...
This is a firm fixed price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc. for an ILLUMINA NEXTSEQ2000 SEQUENCING SYSTEM. The contract has a ceiling value of $576,928.00 and a completion date of July 20, 2026. Illumina is a manufacturer of sequencing and array-based solutions for genetic and genomic analysis, and has previously received prime federal contract and subcontract awards from agencies such as the National Institutes of Health (NIH), Centers for...
This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract, valued at $39,591.55, is for the provision of whole genome reagent kits. The contract does not have a set-aside designation. Illumina is an experienced federal contractor, having been awarded multiple prime contracts and grants across various agencies, including the National Institutes...